Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as PDE5 inhibitors

Details for Australian Patent Application No. 2006313486 (hide)

Owner Pfizer Products Inc.

Inventors Tollefson, Michael Brent

Agent Allens Arthur Robinson

Pub. Number AU-B-2006313486

PCT Pub. Number WO2007/054778

Priority 60/735,320 10.11.05 US

Filing date 31 October 2006

Wipo publication date 18 May 2007

Acceptance publication date 27 October 2011

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/505 (2006.01) - Pyrimidines

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

A61P 13/12 (2006.01) Drugs for disorders of the urinary system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

17 April 2008 PCT application entered the National Phase

  PCT publication WO2007/054778 Priority application(s): WO2007/054778

27 October 2011 Application Accepted

  Published as AU-B-2006313486

23 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006313490-Stabilized lanthanum carbonate compositions

2006313478-Pyrazole derivatives and their medical use